Funding for this research was provided by:
Stand Up To Cancer (SU2C-AACR-DT-20-16)
National Foundation for Cancer Research (None)
Baylor Scott & White Research Institute (BSWRI) and Translational Genomics Research Institute (TGen) Collaboration in Oncology Research (None)
Korean Health Technology R&D Project, Ministry of Health & Welfare, Republic of Korea (HI14C2640)
Received: 6 March 2020
Accepted: 18 August 2020
First Online: 29 September 2020
Ethics approval and consent to participate
: The collection of specimen and associated clinical data used in this study were approved by the Institutional Review Board of Samsung Medical Center (IRB #2015-10-062 and #2018-03-162), the HonorHealth Research Institute (IRB #HHRI-Biomarker Pancreatic Cancer-001), and the Western IRB (IRB #Hhan18-001). All patients who participated in this study provided written informed consent prior to enrollment and specimen collection. This study was performed in accordance with the principles of the Helsinki Declaration.
: Consent has been obtained for the publication of information included in Table SInternalRef removed.
: The authors declare no competing interests.